CMA refers UnitedHealth acquisition to Phase II
Shutterstock/PopTika
The UK’s antitrust enforcer has rejected a divestiture package from UnitedHealth and opened an in-depth probe to determine if the US healthcare giant’s £1.2 billion acquisition of EMIS Group could restrict competition for supplying vital software to the country’s national health service.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now